Alcohol Dependence Clinical Trial
Official title:
Gabapentin for Abstinence Initiation in Alcohol Dependence
Primary Hypotheses:
1. Gabapentin will significantly reduce alcohol consumption and promote abstinence as
compared to placebo. The primary outcome measure will be the number of the heavy drinking
days (defined as any day where the number of standard drinks was at least 5 for men and at
least 4 for women) per week as measured by the timeline follow-back method.
Secondary Hypotheses:
1. Gabapentin will be superior to placebo in reducing alcohol use as measured by percent days
abstinent.
In an 8-week randomized double-blind placebo-controlled outpatient pilot trial the efficacy
of gabapentin in the treatment of alcohol dependence will be studied in 60 patients.
Participants will be randomly assigned to treatment under double-blind conditions with either
1) a fixed dosing schedule of gabapentin or 2) placebo. All participants will receive weekly
supportive behavioral treatment that promotes abstinence from alcohol and other substances,
encourages mutual-support meeting attendance, and facilitates compliance with study
medication. The primary outcome measures will be: the reduction of heavy drinking days per
week as measured by the timeline follow-back method.
Participants will be alcohol-dependent men and nonpregnant women who report drinking a
minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week
over the past 28 days. The daily minimum drinking requirements are consistent with the
commonly accepted definition of "binge drinking." A minimum requirement of having a heavy
drinking episode 4 days a week would select for a population of individuals who are drinking
excessively more days than not. A minimum threshold of weekly alcohol use is set to prevent a
"floor effect" (i.e. participants with minimal alcohol use at baseline would be unable to
demonstrate significant improvement.)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |